Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (101-110 of 232) with videos related to

Pageof 24
Sort By:
Cancer Chemotherapy and Pharmacology|April 29, 2009
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancersAfshin Dowlati, James Posey, Ramesh K Ramanathan, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2011
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studySteven G DuBois, Suzanne Shusterman, Joel M Reid, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasmaJulia Matsumoto, Brian F Kiesel, Robert A Parise, et al.
Cancer|January 2, 2009
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumorsLisa M McGregor, Sheri L Spunt, Victor M Santana, et al.
Cancer Research|December 1, 2011
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusionA Gregory Sorensen, Kyrre E Emblem, Pavlina Polaskova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinUlka N Vaishampayan, Angelika M Burger, Edward A Sausville, et al.
Cancer|January 27, 2009
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyLisa M McGregor, Sheri L Spunt, Wayne L Furman, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumorsBrian S Choi, Dona B Alberti, William R Schelman, et al.
Leukemia & Lymphoma|April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials GroupRena Buckstein, John Kuruvilla, Neil Chua, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 1, 2013
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancerStacey M Stein, Amy Tiersten, Howard S Hochster, et al.
Pageof 24

Showing results (101-110 of 232) with videos related to

Sort By:
Pageof 24
Cancer Chemotherapy and Pharmacology|April 29, 2009
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancersAfshin Dowlati, James Posey, Ramesh K Ramanathan, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2011
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studySteven G DuBois, Suzanne Shusterman, Joel M Reid, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasmaJulia Matsumoto, Brian F Kiesel, Robert A Parise, et al.
Cancer|January 2, 2009
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumorsLisa M McGregor, Sheri L Spunt, Victor M Santana, et al.
Cancer Research|December 1, 2011
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusionA Gregory Sorensen, Kyrre E Emblem, Pavlina Polaskova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinUlka N Vaishampayan, Angelika M Burger, Edward A Sausville, et al.
Cancer|January 27, 2009
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyLisa M McGregor, Sheri L Spunt, Wayne L Furman, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumorsBrian S Choi, Dona B Alberti, William R Schelman, et al.
Leukemia & Lymphoma|April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials GroupRena Buckstein, John Kuruvilla, Neil Chua, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 1, 2013
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancerStacey M Stein, Amy Tiersten, Howard S Hochster, et al.
Pageof 24